harvester schreef op 1 december 2017 23:40:
lopende studies EU:
GLPG2222 alleen GB ongoing andere 3 locaties completed. binnenkort nieuws?
www.clinicaltrialsregister.eu/ctr-sea...EudraCT Number: 2016-002837-31 Sponsor Protocol Number: GLPG2222-CL-201 Start Date*: 2016-12-05
Sponsor Name:Galapagos NV
Full Title: A phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2222 in ivacaftor-treated subjects with Cystic Fibrosis harbouring one F508del CFTR mutation and a second gating (cla...
Medical condition: Cystic Fibrosis
Disease: Version SOC Term Classification Code Term Level
19.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GB (Ongoing) DE (Completed) BE (Completed) CZ (Completed)
Trial results: (No results available)
EudraCT Number: 2016-004477-40 Sponsor Protocol Number: GLPG2222-CL-202 Start Date*: 2017-05-26
Sponsor Name:Galapagos NV
Full Title: A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate multiple doses of GLPG2222 in subjects with Cystic Fibrosis who are homozygous for the F508del mutation
Medical condition: Cystic Fibrosis
Disease: Version SOC Term Classification Code Term Level
19.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GB (Ongoing) NL (Ongoing) BE (Ongoing) ES (Completed)
Trial results: (No results available)
EudraCT Number: 2017-002181-42 Sponsor Protocol Number: GLPG2737-CL-202 Start Date*: 2017-10-27
Sponsor Name:Galapagos NV
Full Title: A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2737 in Orkambi-treated subjects with cystic fibrosis homozygous for the F508del mutation
Medical condition: Cystic fibrosis
Disease: Version SOC Term Classification Code Term Level
20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)